PLX R18

Drug Profile

PLX R18

Alternative Names: PLX R 18; PLX RAD

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Aplastic anaemia; Graft-versus-host disease
  • Preclinical Acute radiation syndrome

Most Recent Events

  • 13 Sep 2017 Pluristem Therapeutics has patent protection for placental expanded (PLX) cells for the treatment of Critical limb ischaemia and muscle regeneration in Hong Kong
  • 17 Aug 2017 US Department of Defense plans a pilot preclinical study for PLX R18 for Acute radiation syndrome
  • 03 May 2017 Pharmacodynamics data from a preclinical study in Acute radiation syndrome released by Pluristem therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top